NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Lilly Collaboration Accelerates RyboDyn's Dark Proteome Targets Toward First-in-Class Therapies SAN DIEGO, /PRNewswire/ -- RyboDyn, Inc., a biotechnology company pioneering first-in-class ...

A large, multicountry European study finds that adults with type 2 diabetes who start empagliflozin experience no increased ...

Oprah Winfrey and Elon Musk endorsed it. And though Indian celebrities haven’t yet admitted to their use, the mystery ...

Mounjaro will soon be available on the NHS across the UK but it's important patients avoid the dangerous 'golden dose' trend ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

Eli Lilly's stock recently took a hit, leaving investors scrambling like pharmacists out of espresso. The company’s ...

The benefits from 2 new Alzheimer’s treatments remain too small to justify the additional cost to the NHS, an independent NICE c ...